Medpace Holdings (MEDP) Price & Analysis

Compare

646 Followers

MEDP Stock Chart & Stats

$608.43

$7.21(2.08%)

At close: Jan 08 4:00 PM EST

$608.43

$7.21(2.08%)

Day’s Range― - ―

52-Week Range$250.05 - $626.26

Previous CloseN/A

Volume64.09K

Average Volume (3M)217.66K

Market Cap

$16.88B

Enterprise Value$14.68B

Total Cash (Recent Filing)$285.35M

Total Debt (Recent Filing)$143.97M

Price to Earnings (P/E)42.6

Beta1.12

Next Earnings

Feb 09, 2026

EPS Estimate

4.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.86

Shares Outstanding28,168,222

10 Day Avg. Volume171,512

30 Day Avg. Volume217,658

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)12.46

Price to Sales (P/S)4.88

P/FCF Ratio17.97

Enterprise Value/Market Cap0.87

Enterprise Value/Revenue6.22

Enterprise Value/Gross Profit20.00

Enterprise Value/Ebitda28.18

Forecast

1Y Price Target

$569.17

Price Target Upside-6.45% Downside

Rating ConsensusHold

Number of Analyst Covering7

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Backlog ExpansionA material increase in awarded but not yet recognized work expanded backlog and signals a sizable pipeline that can convert into revenue if conversion rates remain favorable.

Record BookingsRecord net new business awards and a stronger book-to-bill supported a larger contracted workload that should boost future revenue visibility.

SMid-biotech FocusConcentration on SMid-sized biotech clients taps a faster-growing market segment and reduces exposure to aggressive pricing pressures, supporting premium growth prospects.

Bears Say

Elevated ValuationThe stock trades at elevated multiples relative to peers, leaving limited cushion if growth or margin expectations slip.

Funding Backdrop And Booking SustainabilityA tepid biotech funding environment raises the risk that recent high booking levels may not be sustained, threatening future revenue momentum.

Hiring-driven Margin RiskPlanned acceleration in hiring could push operating costs higher and compress margins before incremental revenue materializes.

Medpace Holdings News

Medpace price target raised to $660 from $655 at Mizuho

Mizuho raised the firm’s price target on Medpace (MEDP) to $660 from $655 and keeps an Outperform rating...

5d ago

MEDP

Medpace price target raised to $525 from $485 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Medpace (MEDP) to $525 from $485 and keeps...

1M ago

MEDP

Jefferies says market thinking ‘backwards’ on FDA one trial proposal

Jefferies says the “market’s thinking is backwards” that a single pivotal drug trial for approvals is a risk...

1M ago

IQV

FTRE

FDA shift in drug study requirements sends trial runners lower

Shares of companies that conduct drug trials on behalf of pharmaceutical companies, such as Icon (ICLR), Iqvia (IQV),...

1M ago

AZN

BMY

FDA to reduce number of trials required for drug approvals, STAT reports

The FDA plans to generally require only one clinical study, rather than the traditional two, for medical product...

1M ago

AZN

BMY

Medpace initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Medpace (MEDP) with a Market Perform rating and $600 price target The firm...

2M ago

MEDP

Medpace Holdings Inc: Key Update on the OPAL Study for Lymphoid Malignancies

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. The OPAL Study, officially titled ‘An...

3M ago

MEDP

Medpace and AVM Biotechnology’s Promising ARDS Study: A Potential Game Changer

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Medpace Holdings Inc. is collaborating with...

3M ago

MEDP

Medpace and Telix Collaborate on Promising Phase 3 Study for Advanced Kidney Cancer

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Medpace Holdings Inc. is collaborating with...

3M ago

MEDP

Medpace and Radiopharm Launch Promising Cancer Study with 177LuBetaBart

Medpace Holdings Inc (($MEDP)), Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

MEDP

Medpace and Radiopharm Theranostics Advance Brain Metastases Imaging Study

Medpace Holdings Inc (($MEDP)), Radiopharm Theranostics Limited (($AU:RAD)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

MEDP

Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study

Medpace Holdings Inc (($MEDP)), Edgewise Therapeutics, Inc. (($EWTX)) announced an update on their ongoing clinical study. Medpace Holdings...

3M ago

EWTX

MEDP

Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF

Tenax Therapeutics (($TENX)), Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Tenax Therapeutics, in...

3M ago

MEDP

TENX

Medpace Holdings Inc: A New Frontier in Carotid Artery Treatment

Medpace Holdings Inc (($MEDP)) announced an update on their ongoing clinical study. Study Overview: The SKYWARD Trans-Carotid IDE...

3M ago

MEDP

MEDP FAQ

What was Medpace Holdings’s price range in the past 12 months?

Medpace Holdings lowest stock price was $250.05 and its highest was $626.25 in the past 12 months.

What is Medpace Holdings’s market cap?

Medpace Holdings’s market cap is $16.88B.

When is Medpace Holdings’s upcoming earnings report date?

Medpace Holdings’s upcoming earnings report date is Feb 09, 2026 which is in 25 days.

How were Medpace Holdings’s earnings last quarter?

Medpace Holdings released its earnings results on Oct 22, 2025. The company reported $3.86 earnings per share for the quarter, beating the consensus estimate of $3.535 by $0.325.

Is Medpace Holdings overvalued?

According to Wall Street analysts Medpace Holdings’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medpace Holdings pay dividends?

Medpace Holdings does not currently pay dividends.

What is Medpace Holdings’s EPS estimate?

Medpace Holdings’s EPS estimate is 4.18.

How many shares outstanding does Medpace Holdings have?

Medpace Holdings has 28,168,222 shares outstanding.

What happened to Medpace Holdings’s price movement after its last earnings report?

Medpace Holdings reported an EPS of $3.86 in its last earnings report, beating expectations of $3.535. Following the earnings report the stock price went up 9.121%.

Which hedge fund is a major shareholder of Medpace Holdings?

Currently, no hedge funds are holding shares in MEDP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Medpace Holdings Stock Smart Score

Neutral

Fundamentals

Return on Equity

73.70%

Trailing 12-Months

Asset Growth

-15.88%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Medpace Holdings

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

Medpace Holdings (MEDP) Earnings & Revenues

Historic Earnings Reports

MEDP Company Deck

MEDP Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted strong revenue and business growth, with significant net new business awards and a record net book-to-bill ratio. Despite these positive aspects, there were challenges related to a higher effective tax rate, lower interest income, and cancellations. Overall, the call demonstrates a strong performance with some areas for improvement.View all MEDP earnings summaries

MEDP Revenue Breakdown

98.00% U.S.

2.00% Other

MEDP Stock 12 Month Forecast

Average Price Target

$569.17

▼(-6.45% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","661":"$661","387.25":"$387.3","478.5":"$478.5","569.75":"$569.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":660,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$660.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":569.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$569.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":462,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$462.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,387.25,478.5,569.75,661],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,569.2153846153846,576.7807692307692,584.3461538461538,591.9115384615385,599.4769230769231,607.0423076923076,614.6076923076923,622.1730769230769,629.7384615384615,637.3038461538462,644.8692307692307,652.4346153846154,{"y":660,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,562.2284615384615,562.806923076923,563.3853846153846,563.9638461538461,564.5423076923076,565.1207692307692,565.6992307692308,566.2776923076923,566.8561538461538,567.4346153846153,568.0130769230769,568.5915384615384,{"y":569.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,561.65,553.9846153846154,546.3192307692308,538.6538461538462,530.9884615384615,523.3230769230769,515.6576923076923,507.9923076923077,500.3269230769231,492.66153846153844,484.99615384615385,477.3307692307692,469.6653846153846,{"y":462,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":332.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":423.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":473.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":584.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":587.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":561.65,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >